
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is a well-established pharmaceutical company with a strong presence in global markets, particularly in the emerging markets. Pfizer has a diverse portfolio of products, with a focus on prescription drugs and vaccines. Despite its recent patent challenges and emerging market controversies, Pfizer's acquisition of Metsera provides promising new growth drivers and differentiation in the market, potentially improving persistence rates and expanding the addressable patient population and market opportunity in obesity. Overall, Pfizer's portfolio, global presence, and potential for continued growth make it a promising stock in the pharmaceutical industry.
Bears say
Pfizer is facing multiple challenges as a major player in the pharmaceutical market, including increasing competition, a shift towards prescription drugs and vaccines being the main source of revenue, and the negative impact of COVID-19. With a large portion of its sales coming from emerging markets and a major patent expiry in 2025, Pfizer's financial outlook is uncertain and may face pressure in the coming years. Despite recent acquisition of Metsera, Pfizer's overall outlook remains negative due to slow growth potential, potential legal challenges, and limited capacity for business development.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares